232 studies found for:    Thrombocytopenia: Clinical Trials
Show Display Options
Rank Status Study
21 Unknown  An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention: Drug: Eculizumab
22 Unknown  An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention: Drug: Eculizumab
23 Completed Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
Conditions: Germ Cell Tumors;   Hepatic Cancer;   Neuroblastoma;   Osteosarcoma;   Rhabdomyosarcoma
Intervention: Drug: Recombinant Human Thrombopoietin
24 Recruiting Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
Condition: Thrombocytopaenia
Interventions: Drug: Eltrombopag olamine;   Other: Placebo
25 Recruiting Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion
Conditions: Blood Platelet Transfusion;   Blood Clotting
Intervention: Drug: Administration of platelet concentrate and taking blood samples
26 Unknown  High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Conventional-dose prednisone group;   Drug: High-dose dexamethasone group
27 Active, not recruiting Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Thrombocytopenia
Interventions: Drug: alvocidib;   Drug: lenalidomide;   Other: pharmacological study;   Other: laboratory biomarker analysis
28 Withdrawn The Plasma Large-Volume Exchange RCT
Conditions: Purpura, Thrombotic Thrombocytopenic;   Hemolytic Uremic Syndrome
Intervention: Procedure: Plasma Exchange
29 Not yet recruiting A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Eltrombopag;   Drug: IVIG infusion
30 Terminated A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
Condition: Chemotherapy-Induced Thrombocytopenia
Intervention: Drug: ONO-7746
31 Recruiting Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Aplastic Anemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Paroxysmal Nocturnal Hemoglobinuria;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Severe Combined Immunodeficiency;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
32 Recruiting A Rollover Study to Provide Continued Treatment With Eltrombopag
Condition: Thrombocytopaenia
Intervention: Drug: ELT
33 Recruiting Interleukin-2 Treatment for Wiskott-Aldrich Syndrome
Conditions: Wiskott-Aldrich Syndrome (WAS);   X-linked Thrombocytopenia
Intervention: Drug: Interleukin-2
34 Terminated
Has Results
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
Condition: Heparin-Induced Thrombocytopenia
Interventions: Drug: fondaparinux;   Drug: warfarin
35 Not yet recruiting Milk-only Lactation Study for Patients on Eltrombopag
Condition: Thrombocytopaenia
Intervention: Drug: eltrombopag
36 Completed
Has Results
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
Condition: Hepatitis C
Interventions: Drug: Eltrombopag;   Drug: Antiviral therapy
37 Completed
Has Results
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients
Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Drug: Ofatumumab 500mg;   Drug: Ofatumumab 1000mg;   Drug: Fludarabine;   Drug: Cyclophosphamide
38 No longer available Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
39 Completed Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
Conditions: Chronic Thrombocytopenia;   Immune Thrombocytopenia
Interventions: Drug: E5501 - Avatrombopag maleate;   Drug: E5501 - Avatrombopag maleate Matching Placebo
40 Completed Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
Condition: Thrombocytopenia
Intervention: Device: Transfusion of Pathogen Inactivated Platelets stored for 6-7 days

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years